Vimy Pharma

Vimy Pharma is a Canadian biotechnology company focused on developing first-in-class remyelinating therapies for neurodegenerative diseases, primarily Multiple Sclerosis. The company's lead program, VIM-001, is a small molecule designed to stimulate the repair of the myelin sheath by promoting the differentiation of oligodendrocyte precursor cells. By addressing the underlying cause of disability progression in MS, Vimy Pharma aims to provide disease-modifying treatments that go beyond current immunomodulatory approaches. The company was founded as a spin-off from the University of Calgary, leveraging the research of Dr. V. Wee Yong. Vimy Pharma is currently advancing its lead candidate through preclinical studies to support future clinical development.